Cargando…
Multikinase inhibitors use in differentiated thyroid carcinoma
Thyroid cancer is the most common endocrine malignancy, and its incidence is increasing. Standard therapy for most patients with localized differentiated thyroid cancer (DTC) includes surgery, radioactive iodine, and thyroid hormone replacement. A minority of thyroid cancer patients requires systemi...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260520/ https://www.ncbi.nlm.nih.gov/pubmed/25506209 http://dx.doi.org/10.2147/BTT.S57619 |
_version_ | 1782348195823616000 |
---|---|
author | Jasim, Sina Ozsari, Levent Habra, Mouhammed Amir |
author_facet | Jasim, Sina Ozsari, Levent Habra, Mouhammed Amir |
author_sort | Jasim, Sina |
collection | PubMed |
description | Thyroid cancer is the most common endocrine malignancy, and its incidence is increasing. Standard therapy for most patients with localized differentiated thyroid cancer (DTC) includes surgery, radioactive iodine, and thyroid hormone replacement. A minority of thyroid cancer patients requires systemic therapy for metastatic disease. Patients with metastatic DTC do not usually benefit from traditional cytotoxic chemotherapy. In this review, we describe newly developed small-molecule tyrosine kinase inhibitors (TKIs) that are being actively tested and used in the management of advanced thyroid cancer. The use of TKIs as a form of molecular targeted therapy is evolving based on understanding of the pathways involved in DTC. Disrupting tumor vascular supply by targeting vascular endothelial growth factor receptor signaling is the most commonly used approach to treat advanced/metastatic DTC. Other mechanisms include targeting BRAF, MAPK/ERK kinase, or mammalian target of rapamycin signaling. Although TKIs appear to have superior efficacy compared to cytotoxic chemotherapy, they can cause substantial adverse effects; symptomatic management of adverse effects, dose adjustment, or cessation of therapy may be required. |
format | Online Article Text |
id | pubmed-4260520 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-42605202014-12-12 Multikinase inhibitors use in differentiated thyroid carcinoma Jasim, Sina Ozsari, Levent Habra, Mouhammed Amir Biologics Review Thyroid cancer is the most common endocrine malignancy, and its incidence is increasing. Standard therapy for most patients with localized differentiated thyroid cancer (DTC) includes surgery, radioactive iodine, and thyroid hormone replacement. A minority of thyroid cancer patients requires systemic therapy for metastatic disease. Patients with metastatic DTC do not usually benefit from traditional cytotoxic chemotherapy. In this review, we describe newly developed small-molecule tyrosine kinase inhibitors (TKIs) that are being actively tested and used in the management of advanced thyroid cancer. The use of TKIs as a form of molecular targeted therapy is evolving based on understanding of the pathways involved in DTC. Disrupting tumor vascular supply by targeting vascular endothelial growth factor receptor signaling is the most commonly used approach to treat advanced/metastatic DTC. Other mechanisms include targeting BRAF, MAPK/ERK kinase, or mammalian target of rapamycin signaling. Although TKIs appear to have superior efficacy compared to cytotoxic chemotherapy, they can cause substantial adverse effects; symptomatic management of adverse effects, dose adjustment, or cessation of therapy may be required. Dove Medical Press 2014-12-04 /pmc/articles/PMC4260520/ /pubmed/25506209 http://dx.doi.org/10.2147/BTT.S57619 Text en © 2014 Jasim et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Jasim, Sina Ozsari, Levent Habra, Mouhammed Amir Multikinase inhibitors use in differentiated thyroid carcinoma |
title | Multikinase inhibitors use in differentiated thyroid carcinoma |
title_full | Multikinase inhibitors use in differentiated thyroid carcinoma |
title_fullStr | Multikinase inhibitors use in differentiated thyroid carcinoma |
title_full_unstemmed | Multikinase inhibitors use in differentiated thyroid carcinoma |
title_short | Multikinase inhibitors use in differentiated thyroid carcinoma |
title_sort | multikinase inhibitors use in differentiated thyroid carcinoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260520/ https://www.ncbi.nlm.nih.gov/pubmed/25506209 http://dx.doi.org/10.2147/BTT.S57619 |
work_keys_str_mv | AT jasimsina multikinaseinhibitorsuseindifferentiatedthyroidcarcinoma AT ozsarilevent multikinaseinhibitorsuseindifferentiatedthyroidcarcinoma AT habramouhammedamir multikinaseinhibitorsuseindifferentiatedthyroidcarcinoma |